BDC Capital's $150M Life Sciences Fund: Canada's Medtech Layer Gets Capital
BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.
Venture capital fuels the companies that reshape industries — from AI infrastructure and fintech to healthcare and defense tech. This hub collects our latest analysis on how VC firms evaluate startups, structure deals, and deploy capital across stages and geographies.
Browse the articles below to research investors, understand deal dynamics, and build a sharper fundraising strategy.
BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.
Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.
Mega buyout funds like KKR's 2026 vehicle aren't traditional VC, but they materially influence late-stage startup exits and crossover rounds.
Blackstone's opportunistic private credit fund is not VC, but its scale directly changes how venture-backed companies refinance, recapitalize, and exit.
Sona's April 2026 Series B announcement reflects continued demand for AI systems embedded in workforce and operations workflows.
Pumpcade's April 2026 pre-seed round reflects continued investor appetite for experimental fintech and market mechanics products.